Jose Florez and his group have contributed to the performance and analysis of high-throughput genomic studies in type 2 diabetes, related traits and complications, in international consortia such as MAGIC, GENIE, DIAGRAM, T2D-GENES, AMP-T2D and SIGMA. He leads the genetic research initiative of the Diabetes Prevention Program, and is the PI of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) and other pharmacogenetic studies at MGH.

Questions being addressed in the lab

  1. What is the genetic architecture of type 2 diabetes and related traits?
  2. What is the impact of genetic variation on physiology and function?
  3. Can this information be translated into better patient care?

Projects underway to answer these questions

  1. Genome-wide association studies for type 2 diabetes

  2. Click to view
  3. Physiological and functional characterization of variants in the SLC16A11 gene

  4. Click to view
  5. Potential for pharmacogenetics in specific populations

  6. Click to view

Answers Found

  1. Genetic determinants of type 2 diabetes to date, by year of publication, effect size and mode of discovery

  2. Click to view
  3. Human glycemic response to a glipizide challenge by genotype at a type 2 diabetes-associated variant in TCF7L2

  4. Click to view
  5. Intensive lifestyle modification abolishes the risk of type 2 diabetes conferred by genetic variants

  6. Click to view